The ‘silent pandemic’ caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology1 and autoimmunity2, are rarely used for infectious diseases and not yet used for antimicrobial resistance3. Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella… Continue reading Monoclonal #antibodies protect against pandrug-resistant #Klebsiella pneumoniae
Tag: antibodies
Dysregulated amino acid sensing drives colorectal cancer growth and metabolic reprogramming leading to chemoresistance
Background and AimsCRC is a devastating disease highly modulated by dietary nutrients. mTORC1 contributes to tumor growth and limits therapy responses. Growth factor signaling is a major mechanism of mTORC1 activation. However, compensatory pathways exist to sustain mTORC1 activity following therapies that target oncogenic growth factor signaling. Amino acids potently activate mTORC1 via amino acid… Continue reading Dysregulated amino acid sensing drives colorectal cancer growth and metabolic reprogramming leading to chemoresistance
Passive transfer of #fibromyalgia symptoms from patients to mice
Fibromyalgia syndrome (FMS) is characterized by widespread pain and tenderness, and patients typically experience fatigue and emotional distress. The etiology and pathophysiology of fibromyalgia are not fully explained and there are no effective drug treatments. Here we show that IgG from FMS patients produced sensory hypersensitivity by sensitizing nociceptive neurons. Mice treated with IgG from… Continue reading Passive transfer of #fibromyalgia symptoms from patients to mice
The #COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal #Antibodies for the Treatment of COVID-19
The COVID-19 Treatment Guidelines Panel (the Panel) recommends using one of the following combination anti-SARS-CoV-2 monoclonal antibodies to treat outpatients with mild to moderate COVID-19 who are at high risk of clinical progression, as defined by the Emergency Use Authorization (EUA) criteria (listed in alphabetical order): Bamlanivimab 700 mg plus etesevimab 1,400 mg (AIIa); or… Continue reading The #COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal #Antibodies for the Treatment of COVID-19
Quick #COVID-19 Healers Sustain Anti-SARS-CoV-2 #Antibody Production
Antibodies are key immune effectors that confer protection against pathogenic threats. The nature and longevity of the antibody response to SARS-CoV-2 infection is not well defined. We charted longitudinal antibody responses to SARS-CoV-2 in 92 subjects after symptomatic COVID-19. Antibody responses to SARS-CoV-2 are unimodally distributed over a broad range, with symptom severity correlating directly… Continue reading Quick #COVID-19 Healers Sustain Anti-SARS-CoV-2 #Antibody Production
A human monoclonal antibody blocking SARS-CoV-2 infection
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on… Continue reading A human monoclonal antibody blocking SARS-CoV-2 infection
2 Medical News 